Refine by
Glucose Level Articles & Analysis
30 news found
Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). ...
Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. “Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 ...
ByBayer AG
” Benefit of Supportive Technology in the Palm of Your Hand Blood glucose meters (BGM) are vital and approximately 95% of people with diabetes who rely on glucose testing use a blood glucose meter. ...
ByLifeScan
Finerenone in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use Short Oral Discussion Area 8 September 20, 2022; 1:00 – 2:00pm (CEST) An additional post-hoc analysis from FIDELITY will investigate the effect of Kerendia by baseline HbA1c categories, HbA1c variability, and diabetes duration in patients with CKD and T2D. Despite well-controlled blood ...
ByBayer AG
VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. ...
At the end of treatment, urinary albumin to creatinine ratio (ACR), renal matrix remodeling, glomerular filtration and interstitial fibrosis were assessed in addition to glucose levels, body weight, and organ weights. About Diabetic Nephropathy Diabetic nephropathy (DN) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are ...
Eight months post infusion, substrate levels in multiple treated tissues were nearly indistinguishable from normal mice. ...
VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. ...
Therapeutic insulin and other treatments do not cure T1D, but simply control blood glucose levels. Even in combination, current immunotherapies can fail to guarantee restoration of insulin independence. ...
“There is a high burden of type 2 diabetes in Japan, and a large proportion of people with type 2 diabetes develop chronic kidney disease. Despite well-controlled blood glucose levels and blood pressure, patients with chronic kidney disease and type 2 diabetes remain at risk of chronic kidney disease progression and cardiovascular death,” said Dr. ...
ByBayer AG
One in 10 adults worldwide have been diagnosed with type 2 diabetes, but a smaller number require multiple medications to control blood glucose levels and avoid serious complications, such as loss of vision and kidney disease. ...
Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor antagonist, is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. “Even when blood glucose levels and blood pressure are well-controlled, the risk of chronic kidney disease progression and ...
ByBayer AG
(NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). ...
“With the Eversense NOW app, Eversense users can enjoy the added peace of mind that comes with knowing friends and family can remotely view real-time glucose data, see trend graphs, and receive real-time glucose alerts from ...
An example of this was the UI of a blood glucose monitor, on which the decimal point, separating numbers, was difficult to decipher. The consequence of this was at home patients misreading their blood glucose levels as 22mmol/L as opposed to 2.2mmol/L and therefore administering a much larger dose of insulin than was required, leading to diabetic ...
Toronto, Canada, July 27, 2021 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01. ...
IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when blood sugar is low and glucagon, a hormone secreted to prevent hypoglycemia, when blood sugar levels drop in response to varying sugar levels (glucose) in the blood. ...
(“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has successfully completed a Phase 1 study evaluating single and multiple ascending doses of ZT-01. ...
(“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). ...
(“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). ...